PT/INR Monitoring for Heparin Infusion
PT/INR monitoring is NOT required for patients receiving unfractionated heparin infusion. Heparin should be monitored using activated partial thromboplastin time (aPTT) or anti-factor Xa assay, not PT/INR, because heparin's mechanism of action primarily affects the intrinsic coagulation pathway, which PT/INR does not adequately reflect 1.
Why PT/INR is Inappropriate for Heparin Monitoring
The fundamental reason PT/INR should not be used is that heparin works through a completely different coagulation pathway than what PT/INR measures:
- Heparin enhances antithrombin III to inhibit factors XIIa, XIa, IXa, and Xa in the intrinsic pathway, which is specifically detected by aPTT, not PT 1
- PT primarily reflects the extrinsic pathway and is relatively insensitive to therapeutic heparin concentrations, making it unsuitable for monitoring heparin therapy 1
- PT/INR is designed to monitor vitamin K antagonists (warfarin), which reduce factors II, VII, IX, and X through a completely different mechanism 2
Correct Monitoring Strategy for Heparin
Use aPTT as the primary monitoring test with the following protocol:
Standard aPTT Monitoring
- Target therapeutic range: aPTT ratio of 1.5-2.5 times control (corresponding to anti-Xa levels of 0.3-0.7 units/mL), though this must be calibrated to your institution's specific reagent 2, 3
- First aPTT should be drawn 6 hours after the initial bolus to allow steady-state distribution 3
- After any dose adjustment, re-measure aPTT in 6 hours until two consecutive therapeutic values are obtained 3
- Once therapeutic, check aPTT every 24 hours and with any significant clinical change 3
Critical Pitfall to Avoid
The commonly quoted "1.5-2.5 × control" aPTT ratio is NOT universally applicable because different aPTT reagents and coagulometers yield widely divergent results for the same heparin concentration 3. Modern aPTT reagents can produce ratios ranging from 1.6-2.7 × control up to 3.7-6.2 × control when measuring the same therapeutic heparin level 3. Your institution must establish its own therapeutic aPTT range calibrated to your specific reagent and analyzer 2, 3.
When to Switch to Anti-Xa Monitoring
Consider anti-factor Xa monitoring instead of aPTT in these situations:
- Heparin resistance (requiring ≥35,000 units/24 hours to achieve therapeutic aPTT) - switch to anti-Xa with target 0.35-0.7 U/mL 3, 1
- Elevated baseline aPTT from lupus anticoagulant, acute phase reactants, or liver disease 1
- High factor VIII or fibrinogen levels that blunt aPTT response 1
- Pediatric patients, particularly infants, where aPTT correlates poorly with heparin levels 1, 4
Anti-Xa monitoring achieves therapeutic anticoagulation more rapidly (28 vs 48 hours), maintains values within goal range longer (66% vs 42% of time), and requires fewer dose adjustments compared to aPTT 5.
When PT/INR IS Monitored (But Not for Heparin)
PT/INR monitoring becomes relevant only when transitioning from heparin to warfarin:
- Warfarin should never be started alone but only under the cover of effective parenteral anticoagulation (heparin or alternative) 2
- Begin warfarin when platelets >150 G/L during heparin therapy 2
- Measure INR daily during co-therapy until INR reaches therapeutic range (typically 2-3) 2
- Continue heparin until INR is therapeutic for at least 24 hours, then discontinue heparin and maintain warfarin alone 2
Special consideration with argatroban: Argatroban artificially elevates INR, requiring measurement of INR 4 hours after stopping argatroban to determine true warfarin effect 2.
Additional Essential Monitoring
Beyond coagulation tests, monitor these parameters: